As we entered the twenty-first century, major advances in the arena of recombinant DNA, hybridoma and transgenic technologies had not only revolutionized the understanding of the etiology and pathogenesis of a number of debilitating and lifethreatening diseases, but also provided novel modes of treatment. Whether it is the clinical application of recombinant cytokines, their agonists or antagonists, monoclonal antibodies, regulatory T cells, gene therapy or the concept of T cell vaccines, all these require understanding of an evolving discipline that worked on the interface of immunology, pathology, pharmacology and genetics called Immunopharmacology.The initial emphasis of the discipline was the development of the drugs that
suppressed immune response to prevent tissue rejection after organ transplantation. The field once considered restricted only to protect the host from invading organisms by mounting immune and inflammatory responses evolved exponentially as we gradually learned about the exciting and sometimes adverse role of the products of the immune response in a very wide range of physiological and pathological settings ranging from cardiovascular, pulmonary, gastrointestinal to neurological function. A number of these products and therapies based on their understanding not only continue to become symptomatic and curative therapeutic agents but have extensively contributed to the early diagnosis of a number of dreadful disorders.click here for download (Source:blog medicalbooks4everyone)
